To control the disease in the coming 2008-20009 flu seasons ,six new versions of the influenza vaccine have been approved by the U.S. health regulators. In these new vaccines Novartis AG’s Fluvirin; GlaxoSmithKline Plc’s Fluarix and FluLaval; CSL Ltd’s Afluria and Sanofi Aventis SA’s Fluzone have been included. AstraZeneca Plc unit MedImmune‘s developed FluMist nasal [...]

Click Here To Continue Reading